Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2008
    Structural Mapping and Drug Design for Prevention and Treatment of Parkinson's Disease

    Objective/Rationale:
    Drugs for treating Parkinson's disease have to date been identified by trial and error. We are using protein structure as a guide for identifying potential drug targets for...

  • Rapid Response Innovation Awards, 2008
    A Pore-Based Method to Sort and Characterize Human Embryonic Stem Cell-Derived Dopaminergic Neurons

    Objective/Rationale:
    Although using human Embryonic Stem Cells (hESCs) as a clinical therapy for Parkinson’s disease is extremely promising, there exists a number of technical obstacles. In particular...

  • Rapid Response Innovation Awards, 2008
    Calpain Inhibitors to treat Parkinsons Disease

    Objective/Rationale: 
    Activation of the calcium activated protease, calpain, has been implicated in the initiation of the process of neuronal degeneration associated with PD. Thus, inhibition of...

  • Rapid Response Innovation Awards, 2008
    Measuring Metabolism of Alpha-synuclein in Extracellular Fluids

    Objective/Rationale:
    Accumulation of the alpha-synuclein protein inside neurons in particular regions of the brain is one of the hallmarks of Parkinson’s disease. Studies suggest that lowering the...

  • Rapid Response Innovation Awards, 2008
    Exploring LRRK2 Substrate(s) for Parkinson Disease by Protein Arrays

    Objective/Rationale: 
    Mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of PD. A major gap in our understanding of how LRRK2 causes PD is the lack of knowledge of...

  • Clinical Intervention Awards, 2008
    Simvastatin for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

    Objective/Rationale:
    Levodopa-induced dyskinesias are caused by an increased response of dopamine receptors to dopamine in the striatum. Among other intracellular pathways, the MAP kinase signaling...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.